share_log

Allspring Global Investments Holdings LLC Boosts Stock Position in BioLife Solutions, Inc. (NASDAQ:BLFS)

Allspring Global Investments Holdings LLC Boosts Stock Position in BioLife Solutions, Inc. (NASDAQ:BLFS)

Allspring Global Investments Holdings LLC 提高了 BioLife Solutions, In
Defense World ·  2023/02/03 04:31

Allspring Global Investments Holdings LLC grew its holdings in shares of BioLife Solutions, Inc. (NASDAQ:BLFS – Get Rating) by 802.2% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,218 shares of the medical equipment provider's stock after buying an additional 1,083 shares during the period. Allspring Global Investments Holdings LLC's holdings in BioLife Solutions were worth $27,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

根据新浪纳斯达克提交给美国证券交易委员会(SEC)的最新文件,该公司第三季度持有的生物生命解决方案公司(BLFS-GET Rating)股票增加了802.2%。该基金持有这家医疗设备提供商的1,218股股票,在此期间又购买了1,083股。截至最近向美国证券交易委员会(Securities and Exchange Commission,美国证券交易委员会)提交的文件,AllSpring Global Investments Holdings LLC持有的BioLife Solutions价值27,000美元。

Several other institutional investors and hedge funds have also made changes to their positions in BLFS. Wipfli Financial Advisors LLC purchased a new stake in BioLife Solutions during the third quarter worth approximately $29,000. Point72 Hong Kong Ltd acquired a new stake in BioLife Solutions during the first quarter worth approximately $36,000. Lazard Asset Management LLC purchased a new stake in shares of BioLife Solutions during the 1st quarter worth approximately $45,000. Ancora Advisors LLC acquired a new position in shares of BioLife Solutions in the 1st quarter valued at $90,000. Finally, KBC Group NV purchased a new position in shares of BioLife Solutions in the 2nd quarter valued at $36,000. 89.82% of the stock is owned by institutional investors and hedge funds.

其他几家机构投资者和对冲基金也改变了他们在BLFS的头寸。Wipfli Financial Advisors LLC在第三季度购买了BioLife Solutions的新股份,价值约2.9万美元。Point72 Hong Kong Ltd在第一季度收购了BioLife Solutions价值约36,000美元的新股份。Lazard Asset Management LLC在第一季度购买了BioLife Solutions的新股份,价值约4.5万美元。Ancora Advisors LLC在第一季度收购了BioLife Solutions的新头寸,价值90,000美元。最后,KBC Group NV在第二季度购买了BioLife Solutions的新头寸,价值3.6万美元。89.82%的股票由机构投资者和对冲基金持有。

Get
到达
BioLife Solutions
生物生命解决方案
alerts:
警报:

BioLife Solutions Price Performance

BioLife解决方案性价比

Shares of NASDAQ:BLFS opened at $25.27 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.76 and a current ratio of 3.68. BioLife Solutions, Inc. has a one year low of $10.40 and a one year high of $29.92. The company has a 50-day simple moving average of $20.72 and a 200-day simple moving average of $21.60. The stock has a market capitalization of $1.08 billion, a price-to-earnings ratio of -10.19 and a beta of 1.86.

纳斯达克:BLFS上周五开盘报25.27美元。该公司的负债权益比率为0.06,速动比率为2.76,流动比率为3.68。BioLife Solutions,Inc.的一年低点为10.40美元,一年高位为29.92美元。该公司的50日简单移动均线切入位为20.72美元,200日简单移动均线切入位为21.60美元。该股市值为10.8亿美元,市盈率为-10.19倍,贝塔系数为1.86。

BioLife Solutions (NASDAQ:BLFS – Get Rating) last posted its quarterly earnings data on Wednesday, November 9th. The medical equipment provider reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.03). BioLife Solutions had a negative net margin of 67.70% and a negative return on equity of 7.50%. The company had revenue of $40.75 million for the quarter, compared to analysts' expectations of $41.63 million. On average, analysts predict that BioLife Solutions, Inc. will post -0.63 EPS for the current year.
生物生命解决方案公司(纳斯达克代码:BLFS-GET Rating)最近一次公布季度收益数据是在11月9日星期三。这家医疗设备提供商报告该季度每股收益(0.15美元),低于(0.03美元)(0.12美元)的普遍预期。BioLife Solutions的净利润率为负67.70%,股本回报率为负7.50%。该公司当季营收为4,075万美元,高于分析师预期的4,163万美元。分析师平均预测,BioLife Solutions,Inc.本年度每股收益将为0.63美元。

Insider Transactions at BioLife Solutions

BioLife Solutions的内幕交易

In related news, CMO Todd Berard sold 6,500 shares of BioLife Solutions stock in a transaction on Wednesday, January 18th. The shares were sold at an average price of $25.04, for a total value of $162,760.00. Following the transaction, the chief marketing officer now directly owns 119,265 shares in the company, valued at approximately $2,986,395.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, COO Greef Roderick De sold 20,000 shares of the firm's stock in a transaction that occurred on Monday, November 14th. The stock was sold at an average price of $23.86, for a total value of $477,200.00. Following the completion of the sale, the chief operating officer now directly owns 96,719 shares of the company's stock, valued at approximately $2,307,715.34. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CMO Todd Berard sold 6,500 shares of the company's stock in a transaction on Wednesday, January 18th. The stock was sold at an average price of $25.04, for a total value of $162,760.00. Following the transaction, the chief marketing officer now directly owns 119,265 shares in the company, valued at approximately $2,986,395.60. The disclosure for this sale can be found here. Insiders sold 113,718 shares of company stock worth $2,466,734 over the last 90 days. 3.30% of the stock is currently owned by insiders.

在相关新闻中,首席营销官托德·贝拉德在1月18日星期三的一次交易中出售了6,500股BioLife Solutions股票。这些股票的平均价格为25.04美元,总价值为162,760.00美元。交易完成后,首席营销官现在直接持有该公司119,265股股票,价值约2,986,395.60美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的,该文件可通过这个环节。在其他新闻方面,首席运营官格里夫·罗德里克·德在11月14日星期一的一笔交易中出售了20,000股公司股票。这只股票的平均售价为23.86美元,总价值为477,200.00美元。出售完成后,首席运营官现在直接拥有该公司96,719股股票,价值约2,307,715.34美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的,该文件可以通过这个环节。此外,首席营销官托德·贝拉德在1月18日星期三的一次交易中出售了6500股公司股票。这只股票的平均售价为25.04美元,总价值为162,760.00美元。交易完成后,首席营销官现在直接持有该公司119,265股股票,价值约2,986,395.60美元。关于这次销售的披露可以找到这里。在过去的90天里,内部人士出售了113,718股公司股票,价值2,466,734美元。3.30%的股份目前由内部人士持有。

Wall Street Analyst Weigh In

华尔街分析师也加入进来

Several equities analysts have issued reports on the stock. StockNews.com upgraded shares of BioLife Solutions to a "sell" rating in a research note on Monday, November 21st. Stephens dropped their price target on BioLife Solutions to $31.00 in a research note on Wednesday, November 16th.

几位股票分析师已经发布了关于该股的报告。在11月21日星期一的一份研究报告中,StockNews.com将BioLife Solutions的股票评级上调至“卖出”。斯蒂芬斯在11月16日星期三的一份研究报告中将BioLife Solutions的目标价下调至31.00美元。

BioLife Solutions Company Profile

BioLife Solutions公司简介

(Get Rating)

(获取评级)

BioLife Solutions, Inc engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs, generic blood stem cell freezing and cell thawing media products and custom product formulation and custom packaging services.

BioLife Solutions,Inc.致力于细胞和组织生物保存工具的开发、制造和营销。其产品包括用于细胞、组织和器官的专有低温储存和冷冻保存冷冻介质产品,通用血液干细胞冷冻和细胞解冻介质产品,以及定制产品配方和定制包装服务。

Recommended Stories

推荐故事

  • Get a free copy of the StockNews.com research report on BioLife Solutions (BLFS)
  • Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
  • Mullen Automotive Stock Gains Momentum On Positive News
  • Harley-Davidson Inc. Stock, Is It Time To Buy?
  • The Bottom Is In For Meta Platforms, Volatility Is Not Over
  • Analyzing Alaska Air's Recent Earnings
  • 免费获取StockNews.com关于BioLife解决方案的研究报告(BLFS)
  • 凯西·伍兹的方舟创新ETF将在2023年反弹?
  • 马伦汽车公司股票因利好消息而上涨
  • 哈雷-戴维森公司的股票,是时候买入了吗?
  • Meta平台的底部已经到了,波动性还没有结束
  • 阿拉斯加航空公司近期收益分析

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.

每日收到有关BioLife解决方案的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对BioLife Solutions和相关公司的最新新闻和分析师评级的每日简要摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发